SavedAdd your journal

Journals / Diagnostic and Interventional Radiology / 2020 / Cilt: 26 - Sayı: 6

TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis

Chong LIU
Tian LI
Jin-tong HE
Haibo SHAO
Pages
575–583
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Meta-analysisshowed that, compared to TACE alone, TACE + MWA resulted in significantly higher 1-, 2-, and3-year overall survival (OS) (1-year OS rate: RR = 1.36, 95% CI 1.28–1.44, P < 0.001; 2-year OS rate:RR = 1.56, 95% CI 1.40–1.74, P < 0.001 and 3-year OS rate: RR = 2.07, 95% CI: 1.67–2.57, P < 0.001).Complete response, partial response, and objective response rates were significantly higher inTACE + MWA than those in TACE alone (P < 0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are many therapeutic options for primary hepatocellular carcinoma (HCC), but very limitedoptions for unresectable HCC with a single lesion larger than 5 cm (Barcelona Clinic Liver Cancer[BCLC] stage A) or with 2-3 nodules beyond 5 cm (BCLC stage B).
📊
Key Findings & Data:PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, and the Wan Fang electronic databases were retrieved to search for studies comparingcombination therapy and TACE monotherapy, published between the earliest available date andAugust 20, 2019.
💡
Conclusion & Impact:Meta-analysisshowed that, compared to TACE alone, TACE + MWA resulted in significantly higher 1-, 2-, and3-year overall survival (OS) (1-year OS rate: RR = 1.36, 95% CI 1.28–1.44, P < 0.001; 2-year OS rate:RR = 1.56, 95% CI 1.40–1.74, P < 0.001 and 3-year OS rate: RR = 2.07, 95% CI: 1.67–2.57, P < 0.001).Complete response, partial response, and objective response rates were significantly higher inTACE + MWA than those in TACE alone (P < 0.001).
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

There are many therapeutic options for primary hepatocellular carcinoma (HCC), but very limitedoptions for unresectable HCC with a single lesion larger than 5 cm (Barcelona Clinic Liver Cancer[BCLC] stage A) or with 2-3 nodules beyond 5 cm (BCLC stage B). Transcatheter arterial chemoembolization (TACE) is considered the first-line treatment for these patients, and combinationtherapy has also been tried. However, the effectiveness of microwave ablation (MWA) combinedwith TACE in the treatment of the above tumors remains to be further confirmed. Therefore, thismeta-analysis aimed to compare the effectiveness of combination therapy and TACE monotherapy on these patients. PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, and the Wan Fang electronic databases were retrieved to search for studies comparingcombination therapy and TACE monotherapy, published between the earliest available date andAugust 20, 2019. A total of 20 articles (reporting 1736 patients) were included. Meta-analysisshowed that, compared to TACE alone, TACE + MWA resulted in significantly higher 1-, 2-, and3-year overall survival (OS) (1-year OS rate: RR = 1.36, 95% CI 1.28–1.44, P < 0.001; 2-year OS rate:RR = 1.56, 95% CI 1.40–1.74, P < 0.001 and 3-year OS rate: RR = 2.07, 95% CI: 1.67–2.57, P < 0.001).Complete response, partial response, and objective response rates were significantly higher inTACE + MWA than those in TACE alone (P < 0.001). Meanwhile, publication bias and sensitivityanalysis were performed and did not show statistical significance.

🔖

Cite This Article

LIU, C., LI, T., HE, J., SHAO, H. (2020). TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis. Diagnostic and Interventional Radiology, Cilt: 26 - Sayı: 6, 575–583. https://ajindex.com/articles/350094

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018
  2. 182–236. [Crossref] 2. Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013
  3. 426–432. [Crossref] 3. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012
  4. 689–700. [Crossref] 4. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009
  5. 905– 913. [Crossref] 5. Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hypothermia 2016
  6. 339– 344. [Crossref] 6. Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol 2015
  7. 1054–1063. [Crossref] 7. Yuan P, Zhang Z, Kuai J. Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma. J BUON 2019
  8. 163–170. 8. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018
  9. 1301–1314. [Crossref] 9. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999
  10. 329–338. [Crossref] 10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010
  11. 52–60. [Crossref] 11. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011
  12. d5928. [Crossref] 12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010
  13. 603–605. [Crossref] 13. Zheng L, Li HL, Guo CY, Luo SX. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodul